Illumine Investment Management LLC purchased a new position in shares of Astrana Health, Inc. (NASDAQ:ASTH - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 18,255 shares of the company's stock, valued at approximately $566,000.
A number of other hedge funds also recently made changes to their positions in ASTH. State of New Jersey Common Pension Fund D raised its position in shares of Astrana Health by 25.4% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 51,287 shares of the company's stock worth $1,617,000 after buying an additional 10,389 shares during the period. Truist Financial Corp acquired a new stake in Astrana Health during the fourth quarter worth about $315,000. Handelsbanken Fonder AB raised its holdings in shares of Astrana Health by 4.7% in the 4th quarter. Handelsbanken Fonder AB now owns 8,900 shares of the company's stock worth $281,000 after purchasing an additional 400 shares during the period. Olympiad Research LP acquired a new position in shares of Astrana Health in the 4th quarter valued at about $287,000. Finally, Illinois Municipal Retirement Fund lifted its stake in shares of Astrana Health by 16.8% in the 4th quarter. Illinois Municipal Retirement Fund now owns 24,987 shares of the company's stock valued at $788,000 after purchasing an additional 3,593 shares in the last quarter. Institutional investors and hedge funds own 52.77% of the company's stock.
Wall Street Analyst Weigh In
Several research analysts recently commented on the stock. Bank of America cut their price target on shares of Astrana Health from $55.00 to $49.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. Barclays started coverage on shares of Astrana Health in a research note on Tuesday, April 1st. They issued an "equal weight" rating and a $36.00 target price on the stock. Truist Financial decreased their price target on shares of Astrana Health from $50.00 to $46.00 and set a "buy" rating for the company in a research report on Tuesday, March 18th. Finally, Robert W. Baird lowered their price target on Astrana Health from $86.00 to $50.00 and set an "outperform" rating for the company in a report on Monday, March 3rd. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $53.29.
View Our Latest Research Report on Astrana Health
Astrana Health Stock Up 6.5%
Astrana Health stock traded up $1.63 during midday trading on Tuesday, hitting $26.70. 330,721 shares of the stock were exchanged, compared to its average volume of 294,812. Astrana Health, Inc. has a 1 year low of $23.12 and a 1 year high of $63.20. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.70 and a quick ratio of 1.70. The firm has a market cap of $1.50 billion, a P/E ratio of 37.08, a P/E/G ratio of 1.35 and a beta of 0.85. The company has a 50 day moving average price of $27.62 and a two-hundred day moving average price of $31.43.
Astrana Health (NASDAQ:ASTH - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.23 by ($0.09). The business had revenue of $620.39 million for the quarter, compared to analysts' expectations of $628.11 million. Astrana Health had a return on equity of 4.90% and a net margin of 1.56%. The firm's revenue was up 53.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.31 earnings per share. On average, sell-side analysts predict that Astrana Health, Inc. will post 1.15 earnings per share for the current fiscal year.
Astrana Health Profile
(
Free Report)
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
See Also
Before you consider Astrana Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.
While Astrana Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
